Human immunodeficiency virus type 1 (HIV1) was confirmed in Zambia in 1983.1 In this study we report clinical observations on 10 leprosy patients infected with HIV 1, admitted to the Leprosy Department of the Salvation Army Hospital, Chikankata, Mazabuka, Zambia between January 1986 and May 1988. This hospital serves as a leprosy referral hospital for the Southern Province of Zambia.
Serological testing for HIVI -antibody was made available for the district hospitals in Zambia at the Microbiology/Pathology Laboratory of the University Teaching Hospital in Lusaka after January 1986. After August 1987 the testing was also done at the medical laboratory of Chikankata Hospital.
Between January 1986 and May 1988 12 leprosy patients were fo und to be infected with HIVI; 7 were tested because of clinical suspicion and 5 were found during a survey. 2 We describe here the 10 available clinical observations-8 of this group were newly diagnosed borderline leprosy patients. The findings in this group were compared with those in a group of 34 newly-diagnosed patients with the same classification, admitted in the same period.
Material and Methods
There were 29 1 admissions to the Leprosy Department of Chikankata Hospital between January 1986 and May 1988: 82 were newly-diagnosed cases; the remaining 209 were referrals for treatment of complications, leprosy having been diagnosed earlier.
Of the 82 new cases, 68 were newly-diagnosed borderline-leprosy patients (including 8 HIVI patients). The files of 34 were readily available for analysis.
The findings in the group of8 patients with HIVI -infection and with newly-diagnosed borderline leprosy were compared with 34 new borderline cases admitted in the same period. From both groups sex, mean age, family history of leprosy, and the time lapsed between the onset of symptoms and reporting for medical attention were compared.
Relevant data concerning their leprosy status and clinical history were compared. The effect of specific therapy was analysed, as were episodes of intercurrent disease other than leprosy reactions.
All the leprosy patients described here were put on multidrug therapy. Those patients fo und to have active neuritis were treated for the first 2 weeks with 40 mg prednisolone then for 4 weeks with 30 mg prednisolone, and thereafter the prednisolone dosage was reduced by 5 mg every 4 weeks until it was zero. The prednisolone was administered once daily, in the morning. Other drugs, e.g. antibiotics, were prescribed as necessary when indicated.
The serological test used to demonstrate the presence of HIV1 -antibodies was the Wellcozyme-anti HTLVIII competitive enzyme-linked immunoassay VK5 1, the same test as is used in the Microbiology/Pathology Laboratory of the University Training Hospital, Lusaka. All the positive results fo und at our laboratory were reconfirmed in Lusaka.
Results
The mean age in the group of 8 patients with newly-diagnosed borderline leprosy and HIVI -infection (group I) and the group of 34 newly-diagnosed borderline leprosy patients (group 2) did not differ significantly (respectively 42·3 and 41·2 years).
More than 50% of the patients had a family member who suffered from leprosy. Group I patients reported somewhat sooner to the hospital than group 2, respectively within 5 months and 9 months after the start of their symptoms. These differences are because the men in group 2 reported on average 12·8 months after the onset of their symptoms.
In both groups 25% of the patients had positive skin smears. About 50% of the patients in both groups reported with active neuritis. In group 2, 10 recovered after specific treatment and 7 improved only partially. The outcome for this complication in Table I .
Newly-diagnosed borderline leprosy + HIV infection (Group I)
Men (4) Women (4 group 1 was much worse: 4 recovered only partially and 1 did not respond at all. Many episodes of intercurrent disease (other than leprosy reactions) were observed in group 1; 2 patients in group 1 died. The findings are described in more detail in Table I . Further clinical details in all the group of 10 HIVI -positive were analysed. Table 2 describes their leprosy assessments, classification, specific therapy and treatment outcomes. Table 3 describes the history of and physical examinations relating to HIVI -infection. None of these patients admitted to drug abuse or to having any homosexual contact. In all, 6 admitted multiple heterosexual contact; 5 had had sexually transmitted diseases (STD) in the past; 7 reported with a generalized lymphadenopathy; I with splenomegaly, I had hepatomegaly; 2 had active STD on admission; and 4 patients presented themselves with I or more afflictions in addition to leprosy. Table 4 describes the observed episodes of intercurrent disease other than reversal reaction and their outcomes; 17 episodes in 7 patients are noted; 1 male patient (BB, 48 yr) died with generalized dermatitis and sepsis; I female (BB, 50 yr) died with fulminant hepatitis.
Discusssion
The group described in this study is very small: studies on larger groups should fo llow soon. On presentation the group of 8 newly-diagnosed borderline leprosy patients with HIVI-infection did not differ very much from the other group of 34 newly-diagnosed borderline leprosy patients in terms of age and presenting signs/symptoms of their leprosy. The only clinical difference was that the group of HIVI -positive patients had poorer outcomes in the treatment of active neuritis. HIVI infects neural macrophages, neural multinuclear cells, microglial cells and sometimes neurones. It can also cause peripheral neuropathy.3 HIVI virus readily infects T4 helper cells, which play a key role in cell-mediated immunity. The leprosy bacillus is known to invade macrophages and Schwann cells. 4 The way the individual handles the leprosy bacillus determines the clinical picture and the outcome of the leprosy infection. 5 The observations in this group suggest that HIVI-infection and leprosy infection enhance each other in terms of development of more fu lminant neuritis in a relatively short time. More observations, also with histopathological studies, will be required to verify this matter. Otherwise, HIVI -infection in these leprosy patients presented itself as it does in patients without leprosy.
The history and equal distribution among women and men points to the pattern of mainly heterosexual transmission of the disease, as earlier observed in Zambia. 6 The high incidence of generalized lymphadenopathy (7 out of 10) and the many episodes of intercurrent disease (16 x infection, I x generalized dermatitis) are evidence of com promised immunity. The group is too small to allow conclusions that HIVI -infection tends to be clinically worse than in other HIVI -positive nonleprosy patients, or that the leprosy is more downgraded, even though it is likely that our patients were already having longer established HIVI -infection with advanced immunological disturbance. Observa tions on more patients in the near future will hopefully clarify this issue.
Conclusions
HIVI -infection does occur in leprosy patients in Zambia and possibly causes early irreversible neuritis, and HIVI -infection in leprosy patients presents clinically in a similar way to HIVI -infection in nonleprosy patients apart from the observations on neuritis.
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